The use of antifibrinolytic drugs to prevent early recurrent aneurysmal subarachnoid haemorrhage.
D000328:Adult; D000368:Aged; D000933:Antifibrinolytic Agents; D001772:Blood Cell Count; D002533:Cerebral Angiography; D003509:Cyclohexanecarboxylic Acids / Q000627:therapeutic use*; D005164:Factor IX; D005165:Factor V; D005167:Factor VII; D005170:Factor X; D005260:Female; D005337:Fibrin / Q000134:cerebrospinal fluid / Q000378:metabolism; D005340:Fibrinogen / Q000378:metabolism; D005343:Fibrinolytic Agents / Q000097:blood / Q000134:cerebrospinal fluid; D006801:Humans; D006830:Hydralazine / Q000627:therapeutic use; D002532:Intracranial Aneurysm / Q000188:drug therapy*; D008297:Male; D008750:Methyldopa / Q000627:therapeutic use; D008875:Middle Aged; D010672:Phenytoin / Q000627:therapeutic use; D011516:Prothrombin; D012008:Recurrence; D013345:Subarachnoid Hemorrhage / Q000401:mortality / Q000517:prevention & control*
D000933:Antifibrinolytic Agents; D003509:Cyclohexanecarboxylic Acids; D005343:Fibrinolytic Agents; D006830:Hydralazine; D008750:Methyldopa; D010672:Phenytoin; D005165:Factor V; D005167:Factor VII; D011516:Prothrombin; D005164:Factor IX; D005170:Factor X; D005337:Fibrin; D005340:Fibrinogen